Harbor Capital Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.88M Sell
66,964
-23,754
-26% -$632K 0.15% 198
2025
Q4
$2.26M Sell
90,718
-69
-0.1% -$1.74K 0.18% 152
2025
Q3
$2.31M Buy
90,787
+2,901
+3% +$71.6K 0.18% 154
2025
Q2
$2.13M Buy
87,886
+72
+0.1% +$1.68K 0.09% 285
2025
Q1
$2.23M Sell
87,814
-26,685
-23% -$698K 0.1% 266
2024
Q4
$3.04M Buy
114,499
+2,805
+3% +$76.1K 0.13% 215
2024
Q3
$3.23M Buy
111,694
+535
+0.5% +$15.6K 0.14% 207
2024
Q2
$3.11M Buy
111,159
+214
+0.2% +$5.89K 0.24% 120
2024
Q1
$3.08M Buy
110,945
+13,462
+14% +$374K 0.4% 36
2023
Q4
$2.81M Sell
97,483
-177
-0.2% -$5.35K 0.54% 32
2023
Q3
$3.24M Hold
97,660
0.69% 22
2023
Q2
$3.58M Hold
97,660
0.72% 19
2023
Q1
$3.98M Buy
97,660
+96,031
+5,895% +$4.15M 1.15% 21
2022
Q4
$83.5K Sell
1,629
-221
-12% -$10.6K 0.08% 101
2022
Q3
$81K Sell
1,850
-1,250
-40% -$60.7K 0.07% 101
2022
Q2
$163K Sell
3,100
-302
-9% -$15.4K 0.12% 93
2022
Q1
$176K Buy
+3,402
New +$177K 0.08% 104

Other funds holding PFE

Harbor Capital Advisors's PFE Position: Q1 2026 in Review

Harbor Capital Advisors reduced its Pfizer (PFE) stake by 26% in Q1 2026, selling an estimated $632K and leaving 66,964 shares worth $1.88M. The position accounts for 0.15% of the portfolio, ranked #198.

Harbor Capital Advisors first reported a position in PFE in Q1 2022 and has held it in 17 quarters since. The position peaked at $3.98M in Q1 2023. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Harbor Capital Advisors held 66,964 shares of Pfizer worth $1.88M as of Q1 2026.
  • Harbor Capital Advisors sold 23,754 Pfizer shares in Q1 2026, an estimated $632K.
  • Pfizer made up 0.15% of Harbor Capital Advisors's portfolio in Q1 2026, its #198 holding.
  • Harbor Capital Advisors first reported a position in Pfizer in Q1 2022 and has held it in 17 quarters since.
  • Harbor Capital Advisors's Pfizer position peaked at $3.98M in Q1 2023.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.